Merck (MRK)
Merck Revenue Growth: 1.30%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MRK Revenue Growth Rankings
| Overall | 36th percentile | 2780 of 4358 |
| Sector | 32nd percentile | 310 of 456 in Healthcare |
| Industry | 44th percentile | 10 of 18 in Drug Manufacturers - Major |
MRK Revenue Growth Range, Past 5 Years
| Minimum | -7.50% | Mar 2009 |
| Maximum | 112.1% | Mar 2010 |
| Average | 20.13% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these MRK related companies
MRK News
Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
May 25, 2:01PM Street Insider
May 25, 2:01PM Street Insider
RT @ScottAdams_Edit Best US dividend stocks with growing cash flow http://stks.co/3yVy $PBI $EEP $NNN $PBCT $PAA $AEP $VVC $MRK $UVV $PAYX
about 2 days ago by eyeonequities
about 2 days ago by eyeonequities
Next week should see surge in biotechs ahead of ASCO presentations 1st week in June. $PFE, $MRK, $VVUS
about 2 days ago by EPS_MomentuM
about 2 days ago by EPS_MomentuM
Merck & Co., Inc. (MRK) Declares $0.42 Quarterly Dividend; 4.5% Yield
May 22, 12:57PM Street Insider
May 22, 12:57PM Street Insider
U.S. Suggests All Baby Boomers Should Get Tested for Hepatitis C
May 18, 4:24PM The Wall Street Journal
May 18, 4:24PM The Wall Street Journal
Go into Pharma to avoid the bloodbath in the markets. Rotation into safety $PFE $MRK $JNJ http://stks.co/3tbu
about 8 days ago by EPS_MomentuM
about 8 days ago by EPS_MomentuM
@MarketsCJR It worked with $MRK, at least. I've bought $MRK shares when they announced a 10000 job cut, around $31 and they've only gone up.
about 9 days ago by mitrado
about 9 days ago by mitrado
Expectations Indicator triggered a Bear Market http://stks.co/3sK7 $MRK $MSFT $PFE $KO
about 9 days ago by LouisEbner
about 9 days ago by LouisEbner
Merck to Present at Bank of America Merrill Lynch 2012 Healthcare Conference
May 16, 8:00AM Business Wire
May 16, 8:00AM Business Wire
$MRK http://stks.co/3ptm Technical Analysis Merck & Co. $MRK Short target 36.03 (fib 38.2%) Chat: http://stks.co/3ptn
about 11 days ago by SergeymPopov
about 11 days ago by SergeymPopov
$MRK Insider Sale: $1.1M of stock sold by Bowles Richard S Iii on May 10, 2012 http://stks.co/3m0L
about 16 days ago by MarketBrief
about 16 days ago by MarketBrief
Listen to $MRK Merck & Co., Inc. at Deutsche Bank AG Health Care Conference - live at 08:00 AM, ondemand after - http://stks.co/3jpD
about 17 days ago by earningscast
about 17 days ago by earningscast
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MRK | 37.55 | -0.05 | -0.13% | 114.30B |
| MRGE | 2.63 | +0.29 | +12.39% | 239.36M |
| MRF | 7.94 | +0.07 | +0.89% | |
| MOVE | 8.07 | -0.15 | -1.82% | 318.28M |
| MOV | 28.40 | -0.63 | -2.17% | 518.87M |
| MCD | 91.05 | -0.48 | -0.52% | 92.74B |
| MBG | 27.66 | +0.03 | +0.12% | |
| MAXY | 5.85 | +0.02 | +0.34% | 162.45M |
| MAR | 38.64 | +0.25 | +0.65% | 12.90B |
| MA | 413.96 | -5.87 | -1.40% | 52.37B |
